CELL INTELLIGENCE · 肿瘤细胞治疗研究

DLBCL 免疫治疗中的巨噬细胞吞噬检查点：从 CD47 到 CD200 的证据成熟度框架

Macrophage phagocytosis checkpoints in DLBCL immunotherapy: an evidence-maturity framework from CD47 to CD200.

外周 CD8⁺ T 细胞克隆性和 NK 细胞扩增标志惰性 B 细胞淋巴瘤对 mosunetuzumab 的早期应答

Peripheral CD8⁺ T-cell clonality and NK-cell expansion mark early response to mosunetuzumab in indolent B-cell lymphoma.

下一代基于抗体的癌症治疗：抗体-药物偶联物和双特异性抗体在血液系统恶性肿瘤和实体瘤中的应用

Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors

难治性特发性炎性肌病相关间质性肺疾病的新型治疗策略

Novel therapies for refractory idiopathic inflammatory myopathy-associated interstitial lung disease.

构建一种高度通用、经优化的 TCR 双特异性支架，用于靶向肿瘤特异性肽-HLA 抗原

Generation of a highly versatile TCR bispecific scaffold optimized for targeting tumor-specific peptide-HLA antigens.

CAR-T 细胞对比双特异性抗体治疗复发/难治性套细胞淋巴瘤：系统综述与荟萃分析

CAR T-cell vs bispecific antibodies in relapsed/refractory mantle cell lymphoma: a systematic review and meta-analysis.

CAR-T 细胞疗法相比双特异性抗体显示出更高的 CR 率，支持其作为 R/R MCL 有效三线治疗的作用。需要随机试验来证实这些发现。

Mosunetuzumab 联合 polatuzumab vedotin 治疗 BTK 抑制剂治疗后的复发/难治性 MCL：一项 2 期研究

Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.

大辩论：CAR-T 细胞疗法对比双特异性抗体治疗 B 细胞淋巴瘤

The Great Debate: CAR-T-Cell Therapy Versus Bispecific Antibodies in B-Cell Lymphoma.

Mosunetuzumab：一种用于滤泡性淋巴瘤的双特异性 CD20 × CD3 抗体，在其他 B-NHL 亚型中具有良好前景

Mosunetuzumab: A bispecific CD20 × CD3 antibody for follicular lymphoma with promising evidence in other B-NHL subtypes.

老年套细胞淋巴瘤：生物学风险分层、体能适应性策略与未满足需求

Mantle Cell Lymphoma in Geriatric Patients: Biologic Risk Stratification, Fitness-Adapted Strategies, and Unmet Needs.